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ABSTRACT 
Purpose: To compare the efficacy of Coupled Plasma Filtration and Adsorption (CPFA) plus 
Continuous Veno-Venous Haemofiltration (CVVH) versus CVVH alone as an adjunct treat-
ment of sepsis in terms of haemodynamic stability, inotropic requirement and inflammatory 
mediators. 
Design and Methods: Prospective randomized controlled trial involving septic patients 
with/without acute kidney injury (AKI) whom were randomized to receive CPFA + CVVH or 
CVVH alone. Haemodynamic parameters including inotropic requirements and inflammatory 
mediators [procalcitonin (PCT) and C reactive protein (CRP)] were measured. 
Results: Twenty-three patients [CPFA + CVVH (n = 11), CVVH (n = 12)] were enrolled. 
Haemodynamic stability occurred earlier and sustained in the CPFA + CVVH group with an 
increase in diastolic blood pressure (p = 0.001 vs. p = 0.226) and mean arterial pressure 
(p = 0.001 vs. p = 0.575) at the end of treatment with no increment in inotropic requirement. 
Both groups had a reduction in PCT and CRP (CPFA + CVVH: p = 0.003, p = 0.026 and 
CVVH: p = 0.008, p = 0.071 respectively). The length of intensive care unit stay, hospital stay 
and 30 day outcomes were similar between the groups. There was an inverse association be-
tween serum albumin and CRP (p = 0.018). Serum albumin positively correlated with systolic 
blood pressure (p = 0.012) and diastolic blood pressure (p = 0.009). We found a trend be-
tween CRP and length of hospital stay (p = 0.056). Patients with a lower PCT at 24 h had a 
better outcome (survival) than those with a higher PCT (p = 0.045). 
Conclusion: CPFA is a feasible, albeit expensive adjunctive extracorporeal treatment that may 
be superior to CVVH alone in the treatment of severe sepsis. 
 
Keywords: Acute kidney injury, CPFA, C reactive protein, CVVH, sepsis, multiorgan dys-
function 
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INTRODUCTION 
Sepsis is one of the leading causes of 
death in critically ill patients with the Sur-
viving Sepsis Campaign reporting mortality 
rates from 30.8 % to 37 % (Dellinger et al., 
2004). Local Malaysian data reported a 
54 % mortality rate in patients with sepsis 
and septicaemia (Gillani et al., 2009). Sep-
sis is characterized by an inflammatory sys-
temic response with the activation of cyto-
kines resulting in endothelial injury, vasodi-
latation and a reduction in blood pressure 
(Levy et al., 2003; Cohen, 1926).  
Acute kidney injury (AKI) is common 
in a wide variety of critical care settings 
and its prevalence in sepsis ranges from 10 
to 40 % (Bellomo et al., 2004; Hoste et al., 
2003; Levy et al., 1996). Although the pre-
sence of multi-organ dysfunction and other 
co-morbidities contribute to the high mor-
tality in sepsis, AKI independently increas-
es morbidity and mortality to nearly 75.2 % 
(Neveu et al., 1996). 
Continuous Renal Replacement Thera-
py (CRRT) has been shown to be effective 
in reducing circulating cytokine levels 
compared to haemodialysis (Bellomo et al., 
1993). De Vriesse et al. (1999) reported that 
CRRT eliminates an appreciable amount of 
TNF-α and other pro-inflammatory cyto-
kines. Hence, CRRT has been proposed as a 
therapeutic option for blood purification in 
sepsis (Bellomo and Ronco, 1999). 
Procalcitonin (PCT), a newer diagnostic 
biomarker of systemic bacterial infection 
has been shown to be a predictor of mortali-
ty in severely septic patient (Meynaar et al., 
2011). Although C reactive protein (CRP) 
is a well recognized marker of sepsis, stud-
ies have shown PCT to be superior (Luz-
zani et al., 2003). CRRT has also been 
shown to reduce PCT (Dahaba et al., 2002; 
Nishikura, 1999). 
Coupled Plasma Filtration and Adsorp-
tion (CPFA) is a novel extracorporeal blood 
purification therapy aimed at non-selective-
ly reducing the circulating levels of both 
pro-inflammatory and anti-inflammatory 
mediators during sepsis and multi-organ 
dysfunction (Tetta et al., 1998, 2000). In 
vitro studies have shown CPFA to be effec-
tive in adsorbing IL-1β, IL-6, IL-8, IL-10 
and TNF-α amongst others (Bellomo et al., 
2002). CPFA has been shown to achieve 
early haemodynamic stability by better 
blood pressure measurements, reduced ino-
tropic support requirement and an im-
provement in the immune response (Cesano 
et al., 2003). Ronco et al. (2002) in his pro-
spective pilot study demonstrated an incre-
ment in mean arterial pressure (MAP) with 
a reduction in noradrenaline requirement 
and reduced serum TNF-α in patients treat-
ed with CPFA compared to Continuous 
Veno-Venous Haemodialysis (CVVH). 
CPFA has been shown to be superior to 
high volume haemofiltration (HVHF) in 
septic patients with multiple organ dysfunc-
tion syndromes (Hu et al., 2012). However, 
no study has directly compared the benefits 
of CPFA in addition to CVVH compared to 
CVVH alone as an adjunctive treatment for 
sepsis. 
At our centre, conventional CVVH and 
HVHF are routinely used as the extracorpo-
real treatment for critically ill patients with 
sepsis and AKI. 
The main objective of this study was to 
compare CPFA + CVVH versus CVVH 
alone as an adjunctive treatment in septic 
patients in terms of:  
(1) Haemodynamic stability and reduction 
in inotropic requirement  
(2) Serum profile of inflammatory bi-
omarkers of sepsis.  
The secondary objective was to com-
pare the duration of intensive care unit 
(ICU) stay, hospital stay and 30 days out-
comes between the patients treated by 
CPFA + CVVH and CVVH alone. 
 
MATERIALS AND METHODS 
This was a prospective randomized con-
trolled clinical trial involving septic patients 
at our institution. The study was approved 
by the Hospital Research and Ethics Com-
mittee (FF 192-2011). 
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Inclusion and exclusion criteria 
Patients had to have either severe sepsis 
or septic shock with/without AKI to be in-
cluded. The criteria used for sepsis is the 
modified version by Bone et al. (1992) and 
adopted by the American College of Chest 
Physicians/Society of Critical Care Medi-
cine Consensus Conference. Patients had to 
be over 18 years of age but less than 75 
years to be included in the study and able to 
give written informed consent. In the pa-
tients who were unable to consent, consent 
was obtained from their legal representa-
tive. 
Our exclusion criteria included patients 
on more than 2 inotropes, history of cardio-
pulmonary resuscitation, prolonged ventila-
tion or poor premorbid status. Patients were 
also excluded if they did not complete 24 h 
of treatment.  
 
Study design 
Patients referred for sepsis with or 
without AKI were assessed for eligibility. 
Those who fulfilled the criteria were ran-
domized to CPFA + CVVH or CVVH alone 
using random number generator software 
(www.sealedenvelope.com) in a 1:1 fash-
ion. The CPFA + CVVH group received 
CPFA for 4 - 8 h followed by CVVH for 
the remaining 24 h. The CVVH group re-
ceived CVVH for 24 h. We collected serum 
for full blood count, urea, creatinine, elec-
trolytes and albumin. Serum inflammatory 
markers (PCT and CRP) were taken at 
baseline and at 24 h (end of treatment).  
 
Patients 
All patients received standard support-
ive care including fluid resuscitation with 
colloids and crystalloids for hypotension 
and started on inotropes (noradrenaline and 
dopamine) to maintain a mean arterial pres-
sure > 65mm Hg. Patients received broad 
spectrum antibiotics that were tailored to 
culture results and managed by the critical 
care physicians. A dual lumen 12F vascular 
catheter (Medcomp, Harleysville, USA) 
was inserted under ultrasound guidance us-
ing Seldinger technique. Placement of vas-
cular access was either in the internal jugu-
lar vein or femoral vein.  
Demographic, clinical and laboratory 
data were collected as part of the standard 
sepsis ICU management. SOFA (Sequential 
Organ Failure Assessment) and APACHE 
II (Acute Physiology and Chronic Health 
Evaluation) scores were used to assess se-
verity of sepsis. All patients’ were followed 
up to 30 days from recruitment. 
 
Coupled plasma filtration and adsorption 
CPFA is an extracorporeal blood purifi-
cation therapy that incorporates three phas-
es. The first phase is plasma filtration. 
Blood from the patient is driven through a 
filter allowing plasma components to pass 
through the membrane pores while blood 
cells are returned to the patient. The plasma 
then passes through a sorbent cartridge 
where a specific resin allows non-specific 
adsorption of pro-inflammatory and anti-
inflammatory mediators and endotoxins. 
This is called ‘purification’. After purifica-
tion, the treated plasma is returned to the 
circulation. Thereafter, blood and purified 
plasma are passed through a haemofilter for 
dialysis of excess water and other small so-
lutes. Adsorption is the accumulation of 
molecules on the surface of a sorbent mate-
rial and depends on the membrane material, 
pH, ionic strength and pore size amongst 
other factors (Formica et al., 2007). CPFA 
duration was until all the resin was ad-
sorbed on the sorbent and at this point the 
CPFA pump was turned off and patients 
continued with CVVH. We did not replace 
the sorbent after it was fully adsorbed. 
CPFA was performed using the HF440 de-
vice (INFOMED, Geneva, Switzerland) 
with a blood flow rate of 180 ml/minute, ul-
trafiltration rate of 35 ml/kg/h and plasma 
flow rate equivalent to 20 % of blood flow 
rate. The haemofilter used for CPFA had a 
surface area of 1.4 m2 (Haemofilter DF-
140, Infomed, Geneva, Switzerland). Ultra-
filtration rate depended on the fluid status 
of the patient. 
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For the CVVH alone group, we used the 
Aquarius CVVH machine (Baxter, Illinois, 
USA) with the Aquamax haemofilter (Bax-
ter, Illinois, USA) with a surface area of 
1.5 m2. The prescribed ultrafiltration rate of 
CVVH was 35 ml/kg/h with a blood flow 
rate of 180 - 200 ml/min. CVVH was per-
formed using bicarbonate replacement flu-
id. We did not routinely change the haemo-
filter within 24 h unless it clotted. If there 
was a clinical need to continue CVVH for 
more than 24 h, then CVVH was continued 
till the clinical condition improved. 
Both groups of patient did not receive 
heparin as most of these patients had a co-
agulopathy due to sepsis. Regular saline 
flushes were used to prevent filter clotting.  
 
Statistical analysis 
Data was analyzed using the SPSS sta-
tistical package version 20.0 (SPSS Inc, 
Chicago, IL, USA). All data were tested for 
normality. Normally distributed numerical 
data were expressed as mean ± standard de-
viation. Non-normally distributed data were 
subjected to non parametric tests and re-
ported as median with inter-quartile range 
(IQR). Students’t-test was used for compar-
ison of quantitative data. Chi-square χ2 test 
with Yates correction or Fishers’ Exact test 
was used for qualitative data. Mann-
Whitney U and Wilcoxon Signed Rank test 
were used if data was not normally distrib-
uted. Pearson correlation and Spearman 
Rank order were used to ascertain correla-
tions. A p value of < 0.05 was considered 
statistically significant. 
 
RESULTS 
This study was carried out over a 6 
month period between August 2011 and 
January 2012. A total of 41 patients were 
screened but only 26 met the inclusion cri-
teria. All 26 patients consented to partici-
pate in the study. However, 3 patients who 
were recruited died shortly after randomiza-
tion and within the first 8 h of treatment. 
Thus only 23 patients (CPFA + CVVH 
(n = 11), CVVH alone (n = 12)) who com-
pleted 24 h of treatment were included in 
the analysis. The baseline demographic and 
laboratory characteristics are shown on Ta-
ble 1. 
 
Table1: Baseline demographics of patients according to treatment groups 
Characteristic CPFA+CVVH (n = 11) CVVH (n = 12) p value
Age (years) 60.45 ± 14.24 62.83 ± 9.23 0.637 
Gender (male : female) 8 : 3 8 : 4 0.765 
Co-morbidities (n) 
Diabetes 
Hypertension 
IHD 
 
4 
1 
1 
 
1 
0 
0 
 
0.113 
0.307 
0.307 
Haemoglobin (g/dL) 11.3 (3.7) 10.1 (1.2) 0.059 
White cell count (x 109) 16.6(6.2) 14.5 (10.2) 0.261 
Platelet (x 109) 50 (131) 101.0 (134) 0.449 
Urea (mmol/L) 17.3 ± 7.8 18.7 ± 7.4 0.667 
Creatinine(umol/L) 248.6 ± 107.4 239.5 ± 51.5 0.801 
eGFR, MDRD(ml/min/1.73 m2) 32.7 ± 28.9 23.1 ± 6.4 0.303 
Albumin (g/L) 21.7 ± 6.4 23.8 ± 6.9 0.476 
CRP (mg/dL) 15.7 (22.8) 12.2 (25.1) 0.525 
PCT (ng/dL) 64.9 (54.3) 43.8 (97.2) 0.288 
Ionotropic support (n) 
Dopamine 
Dopamine dose (mcg/kg/min) 
Noradrenaline 
Noradrenaline dose (mcg/kg/min) 
9/11 
2/11 
8.0 ± 0 
9/11 
0.57 ± 0.35 
9/12 
4/12 
12.13 ± 4.25 
9/12 
0.90 ± 0.85 
0.786 
0.566 
0.265 
0.786 
0.303 
SOFA score 12.18 ± 2.64 11.33 ± 2.71 0.456 
APACHE II score 23.27 ± 7.03 20.58 ± 3.48 0.270 
eGFR,MDRD = estimated Glomerular Filtration Rate Using Modification Of Diet In Renal Disease; PCT = Procalcitonin, 
CRP = Capsular Reactive Protein;SOFA = Sequential Organ Failure Assessment; APACHE II = Acute Physiology and Chronic 
Health Evaluation, all data expressed as mean except () IQR 
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Majority (13/23, 56.5 %) of the pa-
tients were suffering from either a commu-
nity acquired or healthcare associated 
pneumonia. Other causes of sepsis includ-
ed urinary tract infection (3/23, 13 %), in-
tra-abdominal sepsis (2/23, 8.7 %), infec-
tive endocarditis (1/23, 4.3 %) and tuber-
culosis (1/23, 4.3 %). The causative organ-
isms were gram negative organisms (9/23, 
39.1 %), gram positive organisms (5/23, 
21.7 %), no growth (4/23, 17.4 %), fungal 
(2/23, 8.7 %), mixed gram positive and 
gram negative (1/23, 4.3 %) and one pa-
tient each with dengue shock syndrome 
and tuberculosis. 
The blood pressure (BP) and haemody-
namics are as shown on Table 2 and Figure 
1. The inotropic agents used in this study 
were dopamine and noradrenaline. In the 
CPFA group 2 patients were on double in-
otropes where as in the CVVH group 4 pa-
tients were on double inotropes. The mean 
doses of dopamine at baseline in the 
CPFA + CVVH and CVVH alone group 
were 8.0 ± 0 and 12.13 ± 4.25 mcg/kg/min 
respectively (p = 0.265). At 24 h of treat-
ment, the mean doses of dopamine were 
12.00 ± 11.31 and 11.00 ± 10.52 mcg/kg/ 
min respectively (p = 0.919). 
The mean dose of noradrenaline in the 
CPFA + CVVH and CVVH alone group at 
baseline was 0.57 ± 0.35 and 0.90 ± 
0.85 mcg/kg/min respectively (p = 0.303). 
At the end of the study, the mean dose of 
noradrenaline was 0.69 ± 0.67 and 1.13 ± 
1.18 mcg/min respectively (p = 0.343). 
There was no significant change in the 
dose of dopamine or noradrenaline (p = ns) 
in the CPFA arm. Similarly there was no 
change in the dose of dopamine and nora-
drenaline (p = ns) in the CVVH arm from 
the beginning to end of treatment. 
Pre and post treatment serum inflam-
matory markers are shown on Table 3. Ma-
jority of the patients in both treatment 
groups had an ICU admission of less than 
15 days and this shown on Table 4 together 
with 30 days outcomes. 
 
 
Table 2: Haemodynamic parameters of both groups 
 Systolic BP 0 hr 
Systolic BP 
8 hr 
p value 
0–8 hr 
Systolic BP 
24 hr 
p value 
8-24 hr 
p value 
0-24 hr 
CPFA 
CVVH 
Intergroup p value 
113.64 ± 16.31 
105.42 ± 16.51 
0.244 
118.98 ± 13.56 
111.25 ± 19.55 
0.345 
0.248 
0.245 
 
122.55 ± 11.26 
109.58 ± 19.74 
0.07 
0.230 
0.617 
 
0.103 
0.386 
 Diastolic BP 0 hr 
Diastolic BP 
8 hr 
p value 
0-8 hr 
Diastolic BP  
24 hr 
p value 
8-24 hr 
p value 
0-24 hr 
CPFA 
CVVH 
Intergroup p value 
59.91 ±12.13 
58.25 ± 12.43 
0.749 
62.82 ± 12.38 
62.08 ± 12.73 
0.890 
0.079 
0.155 
 
66.18 ± 12.19 
61.75 ± 12.23 
0.394 
0.079 
0.881 
 
< 0.001 
0.226 
 Mean arterial pressure 0 hr 
Mean arterial 
pressure 8 hr 
p value 
0-8 hr 
Mean arterial 
pressure  
24 hr 
p value 
8-24 hr 
p value 
0-24 hr 
CPFA 
CVVH 
Intergroup p value 
64.82 ± 8.89 
74.33 ± 10.89 
0.033 
68.64 ± 10.83 
77.42 ± 12.34 
0.085 
0.057 
0.268 
 
73.09 ± 9.96 
76.33 ± 16.57 
0.580 
0.016 
0.768 
 
< 0.001 
0.575 
 Heart rate 0 hr 
Heart rate 
8 hr 
p value 
0-8 hr 
Heart rate  
24 hr 
p value 
8-24 hr 
p value 
0-24 hr 
CPFA 
CVVH 
Intergroup p value 
108.18 ± 15.84 
113.33 ± 20.71 
0.513 
100.91 ± 9.43 
113.08 ± 17.07 
0.049 
0.218 
0.940 
 
97.27 ± 8.89 
108.83 ± 20.33 
0.097 
0.234 
0.335 
 
0.053 
0.490 
 
BP: Blood pressure (mm Hg) 
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Panel A  
Panel B  
Figure 1: Systolic blood pressure (Panel A) and diastolic blood pressure and mean arterial pressure 
(Panel B) for both groups 
 
 
There was a strong inverse association 
between CRP and albumin (R² = -0.488, 
p = 0.018) and is demonstrated on Figure 
2. We found a trend between serum CRP 
and PCT (R2 = 0.354, p = 0.098). Serum 
CRP also had a trend to correlate with 
length of hospital stay (R2 = 0.404, 
p = 0.056) and length of ICU stay 
(R2 = 0.375, p = 0.078). CRP trended to an 
inverse relationship with both SBP 
(p = 0.085) and MAP (p = 0.059). SOFA 
and APACHE scores correlated well 
(p = 0.007). We found a strong correlation 
between serum albumin and systolic BP 
(R2 = 0.517, p = 0.012) and diastolic BP 
(R2 = 0.532, p = 0.009). 
We explored various parameters with 
outcome but found no significant differ-
ence in APACHE scores/SOFA/CRP and 
PCT in those who survived or died at base-
line. However, we found that those with a 
lower PCT at 24 h post treatment had a 
better outcome (survival) than those with a 
higher PCT (p = 0.045). 
 
 
Figure 2: Correlation between CRP (mg/dl) 
and albumin (g/dL) 
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Table 3: Serum inflammatory mediators at the beginning and end of treatment 
 PCT 0 hr (ng/ml) PCT 24 hr (ng/ml) p value 
CPFA 
CVVH 
Intergroup p value 
64.90(54.30) 
43.77(97.25) 
0.288 
12.65(20.52) 
9.09 (21.16) 
0.651 
0.003 
0.008 
 
 CRP 0 hr (mg/dl) CRP 24 hr (ng/ml) p value 
CPFA 
CVVH 
Intergroup p value 
15.72(22.76) 
12.17 (25.09) 
0.525 
8.51(9.55) 
8.9 (22.45) 
0.786 
0.026 
0.071 
 
PCT = Procalcitonin, CRP = Capsular Reactive Protein 
 
Table 4: Length of ICU and hospital stay and outcomes  
 
 
 
 
 
 
 
 
DISCUSSION 
Sepsis remains a major cause of mor-
bidity and mortality (Oppert et al., 2008). 
Despite a wider armamentarium of antibi-
otics to treat infection, mortality still re-
mains high. This may be because of the 
other effects of sepsis leading to multiple 
organ dysfunction including AKI (Lopes et 
al., 2010). Sepsis is associated with a re-
lease of both pro and anti inflammatory 
mediators that lead to endothelial damage, 
changes in immune and neuroendocrine 
systems, consequently resulting in multi-
organ dysfunction syndrome (Annane et 
al., 2005). There is emerging evidence that 
extracorporeal techniques remove inflam-
matory mediators and improve haemody-
namic stability thereby proposed in the 
treatment of sepsis (Luzzani et al., 2003; 
Klouche et al., 2002). CPFA has been 
shown to restore immune function and hae-
modynamic stability and proposed as an 
adjunct therapy early in the course of sep-
sis and multi-organ dysfunction syndrome 
(Bellomo et al., 2002; Ronco et al., 2002). 
The mean age of our overall study co-
hort was 61.70 ± 11.68 years and is in 
keeping with the literature whereby 26 to 
51 % of patients admitted to ICU were el-
derly (Hennessy et al., 2005). The mean 
estimated GFR in both groups was 
27.7 ± 20.6 ml/min/1.73 m2 and CVVH 
was not instituted for AKI per se but for 
sepsis which tends to occur simultaneously 
(Bagshaw et al., 2008). Despite randomiza-
tion, patients in the CPFA + CVVH group 
had a trend towards a higher baseline se-
rum haemoglobin compared to the CVVH 
group due to one patient in the CVVH 
group having an upper gastrointestinal 
bleed due to severe coagulopathy from 
sepsis. All patients received prophylactic 
proton pump inhibitors. We did not moni-
tor platelets at the end of treatment as we 
did not use heparin and secondly in CPFA, 
no contact of blood cells occurs (including 
platelets) with the sorbent so unlikely to 
get treatment induced thrombocytopenia. 
(Ronco et al., 2003) Both groups had high 
but comparable inflammatory mediators in 
keeping with sepsis. APACHE and SOFA 
CPFA (n = 11) CVVH (n = 12) p value 
Length of ICU stay (days) 10.27 ± 5.95 8.75 ± 5.07 0.515 
Length of hospital stay (days) 23.73 ± 13.21 17.0 ± 9.16 0.167 
30 days outcomes (number/%) 
survived 
died 
Intragroup p value 
 
6 (54.5 %) 
5 (45.5 %) 
1.0 
 
2(16.7 %) 
10(83.3 %) 
0.039 
 
0.289 
0.302 
 
EXCLI Journal 2013;12:681-692 – ISSN 1611-2156 
Received: April 24, 2013, accepted: June 23, 2013, published: August 12, 2013 
 
 
688 
scores were similar at baseline in both 
groups. Pneumonia accounted for the ma-
jority of sepsis in these patients. 
Haemodynamic compromise is a major 
feature of severe sepsis and septic shock 
and in keeping with our study population, 
most of whom required inotropic support. 
We excluded patients who required more 
than two inotropes at baseline as these pa-
tients were unlikely to benefit from any ad-
ditional intervention. Our study demonstra-
ted that patients treated by CPFA + CVVH 
appeared to achieve an earlier and better 
haemodynamic stability compared to those 
in the CVVH only group. 
The systolic BP was similar between 
the CPFA + CVVH and CVVH only group 
at baseline and increased with a trend to 
significance between them at the end of 
24 h (p = 0.07). Both the diastolic BP and 
mean arterial pressure (MAP) were similar 
between both the groups but there was a 
significant improvement at the end of treat-
ment in the CPFA + CVVH group 
(p < 0.001). The MAP was significantly 
lower in the CPFA + CVVH group than in 
the CVVH group at baseline but this re-
duced as the MAP improved significantly 
in the CPFA + CVVH group with both 
groups having similar MAP at the end of 
treatment. More importantly, there was no 
increased requirement of inotropes at 24 h 
of treatment in either group and some pa-
tients were weaned off their inotropes as 
their sepsis responded to multiple interven-
tions including continuous renal replace-
ment therapy. These results demonstrate 
the non selective adsorption of both pro 
and anti-inflammatory leads to a lower 
level of inflammatory mediators in the cir-
culation, thereby reducing vasodilatation of 
the blood vessels and hence leading to an 
improvement in the blood pressure. Ronco 
et al. (2002) demonstrated a significant 
improvement in MAP (p = 0.01), reduced 
noradrenaline requirement (p = 0.003) and 
reduced TNF-α (p = 0.009) in patients 
treated with CPFA compared to continuous 
veno-venous haemodialysis. Formica et al. 
(2007) have also shown an increase in 
MAP, cardiac index, systemic venous re-
sistance index, survival and a 72 % decline 
in CRP in septic shock patients treated 
with CPFA. Hu et al. (2012) found CPFA 
to be superior to high volume haemofiltra-
tion with better in haemodynamic stability 
in patients with multi-organ dysfunction 
syndrome. Our study results concur with 
others in that CPFA offers better haemo-
dynamic support (Ronco et al., 2002; For-
mica et al., 2007, Hu et al., 2012). 
Although gram negative sepsis ac-
counted for sepsis in 39 % of the patients, 
there were similar numbers of patients with 
gram negative sepsis in both groups. Lipo-
polysaccharide is the main component in 
gram negative bacterial cell wall and is in-
volved in mediating the endotoxic shock of 
gram negative sepsis (Shimazu et al., 
1999). There is evidence from in vitro 
studies demonstrating CPFA to restore the 
leucocyte responsiveness to lipopolysac-
charide and thereby reducing the inflam-
matory effects (Ronco et al., 2002). 
Serum PCT is a better marker for the 
identification of severe sepsis and predictor 
of outcome (Meynaar et al., 2011). Serum 
PCT levels have been shown to be more 
sensitive and specific than CRP levels to 
differentiate bacterial from non-infective 
causes of inflammation as well as the abil-
ity to differentiate bacterial from viral 
cause of sepsis (Meisner et al., 1999). 
However, at the time of randomization, no 
PCT levels were available thereby elimi-
nating randomization bias. At the end of 
treatment, both groups had significant re-
duction of both PCT suggesting both mo-
dalities were efficacious in sepsis. Studies 
have shown an improvement in survival by 
removing pro-inflammatory mediators us-
ing haemofiltration (Hoffmann et al., 1995; 
Hoffmann and Faist, 2001). At the end of 
24 h of treatment, serum CRP had de-
creased by 57 % in the CPFA group and 
this finding concurs with others (Formica 
et al., 2003). The PCT levels had also re-
duced by about 75 % in the CPFA group. 
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In our study we demonstrated that PCT at 
24 h of treatment was a predictor of out-
come and patients with a higher PCT were 
unlikely to survive. Studies have shown the 
correlation between PCT and morbidity 
and mortality (Harbarth et al., 2001; 
Boussekey et al., 2005; Castelli et al., 
2006). 
We found no difference in terms of 
length of ICU or total hospital stay be-
tween the two groups. This may be due to 
two reasons. Firstly, we are comparing a 
24 h session of CVVH treatment with or 
without a single cycle of CPFA sorbent 
and this on its own may be inadequate to 
significantly alter outcomes as there are 
multiple factors affecting the outcome ra-
ther than the treatment modality alone. 
Secondly, the sample size was small.  
However, we did show a correlation 
between CRP and length of hospital stay 
which has been previously demonstrated 
(Prieto et al., 2008). In our study we 
demonstrated a direct relationship of serum 
albumin with both systolic and diastolic 
BP and patients with low serum albumin 
had a lower BP. It is well recognized that a 
low serum albumin at sepsis presentation is 
a strong predictor of septic shock (Bossink 
et al., 2001). Serum albumin is also strong-
ly associated with the severity and out-
come of sepsis in critically ill patients 
(Goldwasser and Feldman, 1997). 
We noted in the CVVH group there 
were a higher number of non survivors 
than survivors. However, we couldn’t 
demonstrate any significance with parame-
ters like SOFA score and APACHE II 
score with outcomes. This may be because 
we looked at these scores at baseline, 
whereas other studies have looked at serial 
SOFA scores over 48 h and up to 5 days 
(Ferreira et al., 2001). 
The strength of our study lies in the 
fact that it was a prospective, randomized 
control study and all patients were fol-
lowed for the length of their ICU and hos-
pital stays up to 30 days post treatment. 
The main drawback in our study was cost 
and technicalities of the new sorbents. 
Even though previous studies have been 
promising, this did not take into account of 
cost for each treatment. Due to the prohibi-
tive costs of CPFA disposables, we could 
only afford to provide a single cycle of 
CPFA followed by CVVH per treatment 
whereas most studies provided about 4–8 
cycles of CPFA per treatment session of 
24 h. 
Secondly, the initiation of CRRT in 
ICU was based on many factors apart from 
that of severe sepsis alone and included 
metabolic acidosis, oliguria, uraemia and 
fluid overload. No patient was referred suf-
ficiently early in the course of sepsis with 
normal renal function and as majority of 
our patients had AKI, this may also explain 
the high mortality rate in this cohort. 
Thirdly, due to the small sample size, we 
could not ascertain the validity of ‘signifi-
cant’ results. A larger prospective random-
ized controlled trial involving multiple 
centres is indicated to confirm these pre-
liminary findings. 
 
CONCLUSION 
Our study showed that treatment with 
CPFA + CVVH compared with CVVH 
alone resulted in earlier and sustained 
haemodynamic stability. Both therapies 
significantly reduced the serum biomarkers 
of sepsis. These initial results do suggest 
that CPFA is indicated as the extracorpore-
al treatment of choice in selected patients 
with severe sepsis. 
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